Zydus has received the EIR report from the USFDA for the inspection conducted at its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated (VAI).

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.